Loading...

Advancements In Genomics And Rare Therapies Will Expand Prospects

Published
21 Mar 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
US$86.05
66.2% undervalued intrinsic discount
04 Sep
US$29.08
Loading
1Y
-47.7%
7D
-1.3%

Author's Valuation

US$86.0566.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 0.74%

Shared on24 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on17 Apr 25
Fair value Increased 0.94%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 54.2x to 60.7x.

Shared on09 Apr 25
Fair value Increased 2.76%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 2.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.